Global Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Comprehensive Study by Treatment (Immunotherapy, Chemotherapy, Cancer Surgery, Bone Marrow Transplant, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Diagnosis (Blood and Urine Tests, Neurological Examination, Imaging Studies, Biopsy) Players and Region - Global Market Outlook to 2029

Pediatric Neuroblastoma Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pediatric Neuroblastoma Treatment
Pediatric neuroblastoma is a rare and aggressive childhood cancer that develops from nerve cells outside the brain and spinal cord, most commonly in infants and young children. Pediatric Neuroblastoma is a cancerous tumor in which malignant (cancer) cells form in neuroblasts (immature nerve tissue) in the adrenal glands, neck, chest, or spinal cord. The abnormal cells are often found in the nerve tissue that is present in the unborn baby and later develops into a detectable tumor. It is rare in kids older than 10 years of age and occasionally occurs in adults. Its treatment is based on whether the tumor is low, intermediate or high risk. The treatment of neuroblastoma may involve chemotherapy, radiation therapy, bone marrow transplant and others.

AttributesDetails
Study Period2018-2029
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pediatric Neuroblastoma Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

United Therapeutics (United States), Apeiron Biologics AG (Austria), Pfizer Inc. (United States), Bayer AG (Germany), Baxter International Inc. (United States), Cellectar Biosciences (United States) and MacroGenics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bluebell Biopharma Ltd. (United Kingdom), Bayer AG (Germany), Janssen Pharmaceuticals (United States) and Meda Pharmaceuticals (Sweden).

Segmentation Overview
AMA Research has segmented the market of Global Pediatric Neuroblastoma Treatment market by and Region.



On the basis of geography, the market of Pediatric Neuroblastoma Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Immunotherapy will boost the Pediatric Neuroblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Pediatric Neuroblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Pediatric Neuroblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Blood and Urine Tests will boost the Pediatric Neuroblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Cancer Research and Development Activities and Rise in the Awareness about Cancer Treatment among People

Market Growth Drivers:
Increased Demand for Effective Treatment for Neuroblastoma and Increased Number of Diagnostic Centres and Hospitals

Challenges:
High Cost of the Treatments

Restraints:
Side Effects of the Cancer Treatments is the Restraining Factor for Pediatric Neuroblastoma Treatment Market

Opportunities:
Growing Healthcare Industry Worldwide and Increased Government Funding for Research and Development Activities

Market Leaders and their expansionary development strategies
In December 2023, St. Jude Children's Research Hospital and Janssen Pharmaceuticals partner to conduct a clinical trial using Dinutuximab in combination with other therapies for newly diagnosed high-risk neuroblastoma, aiming to improve long-term survival rates.
In October 2023, Children's Oncology Group (COG) launches a large-scale clinical trial investigating the combination of immunotherapy and targeted therapy for high-risk neuroblastoma, aiming to further improve outcomes.


Key Target Audience
Pediatric Neuroblastoma Treatment Providers, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Treatment
  • Immunotherapy
  • Chemotherapy
  • Cancer Surgery
  • Bone Marrow Transplant
  • Others

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Diagnosis
  • Blood and Urine Tests
  • Neurological Examination
  • Imaging Studies
  • Biopsy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Demand for Effective Treatment for Neuroblastoma
      • 3.2.2. Increased Number of Diagnostic Centres and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. High Cost of the Treatments
    • 3.4. Market Trends
      • 3.4.1. Increased Cancer Research and Development Activities
      • 3.4.2. Rise in the Awareness about Cancer Treatment among People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pediatric Neuroblastoma Treatment, by Treatment, End-users, Distribution Channel, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pediatric Neuroblastoma Treatment (Value)
      • 5.2.1. Global Pediatric Neuroblastoma Treatment by: Treatment (Value)
        • 5.2.1.1. Immunotherapy
        • 5.2.1.2. Chemotherapy
        • 5.2.1.3. Cancer Surgery
        • 5.2.1.4. Bone Marrow Transplant
        • 5.2.1.5. Others
      • 5.2.2. Global Pediatric Neuroblastoma Treatment by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Pediatric Neuroblastoma Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Pediatric Neuroblastoma Treatment by: Diagnosis (Value)
        • 5.2.4.1. Blood and Urine Tests
        • 5.2.4.2. Neurological Examination
        • 5.2.4.3. Imaging Studies
        • 5.2.4.4. Biopsy
      • 5.2.5. Global Pediatric Neuroblastoma Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Pediatric Neuroblastoma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. United Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Apeiron Biologics AG (Austria)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter International Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cellectar Biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MacroGenics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Pediatric Neuroblastoma Treatment Sale, by Treatment, End-users, Distribution Channel, Diagnosis and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Pediatric Neuroblastoma Treatment (Value)
      • 7.2.1. Global Pediatric Neuroblastoma Treatment by: Treatment (Value)
        • 7.2.1.1. Immunotherapy
        • 7.2.1.2. Chemotherapy
        • 7.2.1.3. Cancer Surgery
        • 7.2.1.4. Bone Marrow Transplant
        • 7.2.1.5. Others
      • 7.2.2. Global Pediatric Neuroblastoma Treatment by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Pediatric Neuroblastoma Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Pediatric Neuroblastoma Treatment by: Diagnosis (Value)
        • 7.2.4.1. Blood and Urine Tests
        • 7.2.4.2. Neurological Examination
        • 7.2.4.3. Imaging Studies
        • 7.2.4.4. Biopsy
      • 7.2.5. Global Pediatric Neuroblastoma Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pediatric Neuroblastoma Treatment: by Treatment(USD Million)
  • Table 2. Pediatric Neuroblastoma Treatment Immunotherapy , by Region USD Million (2018-2023)
  • Table 3. Pediatric Neuroblastoma Treatment Chemotherapy , by Region USD Million (2018-2023)
  • Table 4. Pediatric Neuroblastoma Treatment Cancer Surgery , by Region USD Million (2018-2023)
  • Table 5. Pediatric Neuroblastoma Treatment Bone Marrow Transplant , by Region USD Million (2018-2023)
  • Table 6. Pediatric Neuroblastoma Treatment Others , by Region USD Million (2018-2023)
  • Table 7. Pediatric Neuroblastoma Treatment: by End-users(USD Million)
  • Table 8. Pediatric Neuroblastoma Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 9. Pediatric Neuroblastoma Treatment Clinics , by Region USD Million (2018-2023)
  • Table 10. Pediatric Neuroblastoma Treatment Others , by Region USD Million (2018-2023)
  • Table 11. Pediatric Neuroblastoma Treatment: by Distribution Channel(USD Million)
  • Table 12. Pediatric Neuroblastoma Treatment Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Pediatric Neuroblastoma Treatment Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Pediatric Neuroblastoma Treatment Online Pharmacies , by Region USD Million (2018-2023)
  • Table 15. Pediatric Neuroblastoma Treatment: by Diagnosis(USD Million)
  • Table 16. Pediatric Neuroblastoma Treatment Blood and Urine Tests , by Region USD Million (2018-2023)
  • Table 17. Pediatric Neuroblastoma Treatment Neurological Examination , by Region USD Million (2018-2023)
  • Table 18. Pediatric Neuroblastoma Treatment Imaging Studies , by Region USD Million (2018-2023)
  • Table 19. Pediatric Neuroblastoma Treatment Biopsy , by Region USD Million (2018-2023)
  • Table 20. South America Pediatric Neuroblastoma Treatment, by Country USD Million (2018-2023)
  • Table 21. South America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 22. South America Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 23. South America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 24. South America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 25. Brazil Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 27. Brazil Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 28. Brazil Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 29. Argentina Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 30. Argentina Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 31. Argentina Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 32. Argentina Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 33. Rest of South America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 34. Rest of South America Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 35. Rest of South America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 36. Rest of South America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 37. Asia Pacific Pediatric Neuroblastoma Treatment, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 39. Asia Pacific Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 40. Asia Pacific Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 41. Asia Pacific Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 42. China Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 43. China Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 44. China Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 45. China Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 46. Japan Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 47. Japan Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 48. Japan Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 49. Japan Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 50. India Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 51. India Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 52. India Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 53. India Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 54. South Korea Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 55. South Korea Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 56. South Korea Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 57. South Korea Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 58. Taiwan Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 59. Taiwan Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 60. Taiwan Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 61. Taiwan Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 62. Australia Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 63. Australia Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 64. Australia Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 65. Australia Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 70. Europe Pediatric Neuroblastoma Treatment, by Country USD Million (2018-2023)
  • Table 71. Europe Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 72. Europe Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 73. Europe Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 74. Europe Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 75. Germany Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 76. Germany Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 77. Germany Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 78. Germany Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 79. France Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 80. France Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 81. France Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 82. France Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 83. Italy Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 84. Italy Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 85. Italy Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 86. Italy Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 87. United Kingdom Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 88. United Kingdom Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 89. United Kingdom Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 90. United Kingdom Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 91. Netherlands Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 92. Netherlands Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 93. Netherlands Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 94. Netherlands Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 95. Rest of Europe Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 96. Rest of Europe Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 97. Rest of Europe Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 98. Rest of Europe Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 99. MEA Pediatric Neuroblastoma Treatment, by Country USD Million (2018-2023)
  • Table 100. MEA Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 101. MEA Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 102. MEA Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 103. MEA Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 104. Middle East Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 105. Middle East Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 106. Middle East Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 107. Middle East Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 108. Africa Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 109. Africa Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 110. Africa Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 111. Africa Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 112. North America Pediatric Neuroblastoma Treatment, by Country USD Million (2018-2023)
  • Table 113. North America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 114. North America Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 115. North America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 116. North America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 117. United States Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 118. United States Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 119. United States Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 120. United States Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 121. Canada Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 122. Canada Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 123. Canada Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 124. Canada Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 125. Mexico Pediatric Neuroblastoma Treatment, by Treatment USD Million (2018-2023)
  • Table 126. Mexico Pediatric Neuroblastoma Treatment, by End-users USD Million (2018-2023)
  • Table 127. Mexico Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 128. Mexico Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Pediatric Neuroblastoma Treatment: by Treatment(USD Million)
  • Table 137. Pediatric Neuroblastoma Treatment Immunotherapy , by Region USD Million (2024-2029)
  • Table 138. Pediatric Neuroblastoma Treatment Chemotherapy , by Region USD Million (2024-2029)
  • Table 139. Pediatric Neuroblastoma Treatment Cancer Surgery , by Region USD Million (2024-2029)
  • Table 140. Pediatric Neuroblastoma Treatment Bone Marrow Transplant , by Region USD Million (2024-2029)
  • Table 141. Pediatric Neuroblastoma Treatment Others , by Region USD Million (2024-2029)
  • Table 142. Pediatric Neuroblastoma Treatment: by End-users(USD Million)
  • Table 143. Pediatric Neuroblastoma Treatment Hospitals , by Region USD Million (2024-2029)
  • Table 144. Pediatric Neuroblastoma Treatment Clinics , by Region USD Million (2024-2029)
  • Table 145. Pediatric Neuroblastoma Treatment Others , by Region USD Million (2024-2029)
  • Table 146. Pediatric Neuroblastoma Treatment: by Distribution Channel(USD Million)
  • Table 147. Pediatric Neuroblastoma Treatment Hospital Pharmacies , by Region USD Million (2024-2029)
  • Table 148. Pediatric Neuroblastoma Treatment Retail Pharmacies , by Region USD Million (2024-2029)
  • Table 149. Pediatric Neuroblastoma Treatment Online Pharmacies , by Region USD Million (2024-2029)
  • Table 150. Pediatric Neuroblastoma Treatment: by Diagnosis(USD Million)
  • Table 151. Pediatric Neuroblastoma Treatment Blood and Urine Tests , by Region USD Million (2024-2029)
  • Table 152. Pediatric Neuroblastoma Treatment Neurological Examination , by Region USD Million (2024-2029)
  • Table 153. Pediatric Neuroblastoma Treatment Imaging Studies , by Region USD Million (2024-2029)
  • Table 154. Pediatric Neuroblastoma Treatment Biopsy , by Region USD Million (2024-2029)
  • Table 155. South America Pediatric Neuroblastoma Treatment, by Country USD Million (2024-2029)
  • Table 156. South America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 157. South America Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 158. South America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 159. South America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 160. Brazil Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 161. Brazil Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 162. Brazil Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 163. Brazil Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 164. Argentina Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 165. Argentina Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 166. Argentina Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 167. Argentina Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 168. Rest of South America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 169. Rest of South America Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 170. Rest of South America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 171. Rest of South America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 172. Asia Pacific Pediatric Neuroblastoma Treatment, by Country USD Million (2024-2029)
  • Table 173. Asia Pacific Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 174. Asia Pacific Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 175. Asia Pacific Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 176. Asia Pacific Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 177. China Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 178. China Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 179. China Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 180. China Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 181. Japan Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 182. Japan Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 183. Japan Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 184. Japan Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 185. India Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 186. India Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 187. India Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 188. India Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 189. South Korea Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 190. South Korea Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 191. South Korea Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 192. South Korea Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 193. Taiwan Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 194. Taiwan Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 195. Taiwan Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 196. Taiwan Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 197. Australia Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 198. Australia Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 199. Australia Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 200. Australia Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 201. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 202. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 203. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 204. Rest of Asia-Pacific Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 205. Europe Pediatric Neuroblastoma Treatment, by Country USD Million (2024-2029)
  • Table 206. Europe Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 207. Europe Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 208. Europe Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 209. Europe Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 210. Germany Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 211. Germany Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 212. Germany Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 213. Germany Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 214. France Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 215. France Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 216. France Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 217. France Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 218. Italy Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 219. Italy Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 220. Italy Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 221. Italy Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 222. United Kingdom Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 223. United Kingdom Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 224. United Kingdom Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 225. United Kingdom Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 226. Netherlands Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 227. Netherlands Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 228. Netherlands Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 229. Netherlands Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 230. Rest of Europe Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 231. Rest of Europe Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 232. Rest of Europe Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 233. Rest of Europe Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 234. MEA Pediatric Neuroblastoma Treatment, by Country USD Million (2024-2029)
  • Table 235. MEA Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 236. MEA Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 237. MEA Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 238. MEA Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 239. Middle East Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 240. Middle East Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 241. Middle East Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 242. Middle East Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 243. Africa Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 244. Africa Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 245. Africa Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 246. Africa Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 247. North America Pediatric Neuroblastoma Treatment, by Country USD Million (2024-2029)
  • Table 248. North America Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 249. North America Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 250. North America Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 251. North America Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 252. United States Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 253. United States Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 254. United States Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 255. United States Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 256. Canada Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 257. Canada Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 258. Canada Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 259. Canada Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 260. Mexico Pediatric Neuroblastoma Treatment, by Treatment USD Million (2024-2029)
  • Table 261. Mexico Pediatric Neuroblastoma Treatment, by End-users USD Million (2024-2029)
  • Table 262. Mexico Pediatric Neuroblastoma Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 263. Mexico Pediatric Neuroblastoma Treatment, by Diagnosis USD Million (2024-2029)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pediatric Neuroblastoma Treatment: by Treatment USD Million (2018-2023)
  • Figure 5. Global Pediatric Neuroblastoma Treatment: by End-users USD Million (2018-2023)
  • Figure 6. Global Pediatric Neuroblastoma Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Pediatric Neuroblastoma Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 9. Asia Pacific Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 10. Europe Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 11. MEA Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 12. North America Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 13. Global Pediatric Neuroblastoma Treatment share by Players 2023 (%)
  • Figure 14. Global Pediatric Neuroblastoma Treatment share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. United Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 17. United Therapeutics (United States) Revenue: by Geography 2023
  • Figure 18. Apeiron Biologics AG (Austria) Revenue, Net Income and Gross profit
  • Figure 19. Apeiron Biologics AG (Austria) Revenue: by Geography 2023
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 24. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Cellectar Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cellectar Biosciences (United States) Revenue: by Geography 2023
  • Figure 28. MacroGenics (United States) Revenue, Net Income and Gross profit
  • Figure 29. MacroGenics (United States) Revenue: by Geography 2023
  • Figure 30. Global Pediatric Neuroblastoma Treatment: by Treatment USD Million (2024-2029)
  • Figure 31. Global Pediatric Neuroblastoma Treatment: by End-users USD Million (2024-2029)
  • Figure 32. Global Pediatric Neuroblastoma Treatment: by Distribution Channel USD Million (2024-2029)
  • Figure 33. Global Pediatric Neuroblastoma Treatment: by Diagnosis USD Million (2024-2029)
  • Figure 34. South America Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 35. Asia Pacific Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 36. Europe Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 37. MEA Pediatric Neuroblastoma Treatment Share (%), by Country
  • Figure 38. North America Pediatric Neuroblastoma Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • United Therapeutics (United States)
  • Apeiron Biologics AG (Austria)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • Baxter International Inc. (United States)
  • Cellectar Biosciences (United States)
  • MacroGenics (United States)
Additional players considered in the study are as follows:
Bluebell Biopharma Ltd. (United Kingdom) , Bayer AG (Germany) , Janssen Pharmaceuticals (United States) , Meda Pharmaceuticals (Sweden)
Select User Access Type

Key Highlights of Report


Jan 2024 227 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pediatric Neuroblastoma Treatment Market Quantitative research analysis
Global Pediatric Neuroblastoma Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as United Therapeutics (United States), Apeiron Biologics AG (Austria), Pfizer Inc. (United States), Bayer AG (Germany), Baxter International Inc. (United States), Cellectar Biosciences (United States) and MacroGenics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Cancer Research and Development Activities " is seen as one of major influencing trends for Pediatric Neuroblastoma Treatment Market during projected period 2023-2029.
The Pediatric Neuroblastoma Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pediatric Neuroblastoma Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Rare Disease Treatment Comprehensive Study by Type (Cancer, -Non-Hodgkin Lymphoma, -Acute Myeloid Leukemia, -Pancreatic Cancer, -Ovarian Cancer, -Multiple Myeloma, -Renal Cell Carcinoma, -Others, Met...
$ 3750
Infectious Diseases Comprehensive Study by Type (Reagents and Kits, Instrument, Software), Infectious Disease Type (Viral Infections, Bacterial Infections, Fungal Infections, Parasitic Infections, Ot...
$ 3800
Renal Denervation Treatment Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Others), Technology (Ultrasound, Radiofrequency, Ultrasound, Micro-infusion), Diseases (Hyperte...
$ 3350
Chronic Fatigue Syndrome Treatment Comprehensive Study by Application (Hospitals, Clinics, Research Institutes), Distribution Channel (Hospital Pharmacies, Retails Pharmacies, Online Pharmacies), Mod...
$ 3750
Childhood Vaccines Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, Others), Techn...
$ 3750
Bone Marrow Transplantation Comprehensive Study by Type (Allogeneic Bone Marrow Transplant, Autologous Bone Marrow Transplant), Indication (Leukemia, Lymphoma, Myeloma, Myelodysplasia, Myeloprolifera...
$ 3650